ZA200401108B - Biologically active peptides - Google Patents
Biologically active peptides Download PDFInfo
- Publication number
- ZA200401108B ZA200401108B ZA200401108A ZA200401108A ZA200401108B ZA 200401108 B ZA200401108 B ZA 200401108B ZA 200401108 A ZA200401108 A ZA 200401108A ZA 200401108 A ZA200401108 A ZA 200401108A ZA 200401108 B ZA200401108 B ZA 200401108B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptide
- amino acid
- acid sequence
- group
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 237
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 49
- 230000012010 growth Effects 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 208000006454 hepatitis Diseases 0.000 claims description 18
- 231100000283 hepatitis Toxicity 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 201000008383 nephritis Diseases 0.000 claims description 18
- 208000002672 hepatitis B Diseases 0.000 claims description 17
- 230000005965 immune activity Effects 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 6
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 98
- 235000002639 sodium chloride Nutrition 0.000 description 92
- 239000011780 sodium chloride Substances 0.000 description 92
- 210000004027 cell Anatomy 0.000 description 31
- 108010034465 CMS 024 Proteins 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 108010050904 Interferons Proteins 0.000 description 16
- 102000014150 Interferons Human genes 0.000 description 16
- 229940079322 interferon Drugs 0.000 description 16
- 108010085335 Pro-Thr-Thr-Lys-Thr-Tyr-Phe-Pro-His-Phe Proteins 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 13
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 230000002399 phagocytotic effect Effects 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 241001504469 Anthus Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- -1 CMS027 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ORYMMTRPKVTGSJ-XVKPBYJWSA-N Gln-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O ORYMMTRPKVTGSJ-XVKPBYJWSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90449201A | 2001-07-13 | 2001-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401108B true ZA200401108B (en) | 2006-05-31 |
Family
ID=25419251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401108A ZA200401108B (en) | 2001-07-13 | 2004-02-11 | Biologically active peptides |
| ZA200509838A ZA200509838B (en) | 2001-07-13 | 2005-12-05 | Biologically active peptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509838A ZA200509838B (en) | 2001-07-13 | 2005-12-05 | Biologically active peptides |
Country Status (24)
| Country | Link |
|---|---|
| EP (3) | EP1478659B1 (de) |
| JP (3) | JP4213581B2 (de) |
| KR (2) | KR100889993B1 (de) |
| AT (2) | ATE414099T1 (de) |
| AU (1) | AU2002319423B2 (de) |
| BR (1) | BR0210252A (de) |
| CA (2) | CA2452417C (de) |
| DE (2) | DE60229883D1 (de) |
| DK (2) | DK1790655T3 (de) |
| ES (2) | ES2345842T3 (de) |
| HK (2) | HK1066552A1 (de) |
| IL (2) | IL159827A0 (de) |
| MX (1) | MXPA03011190A (de) |
| MY (1) | MY138219A (de) |
| NO (2) | NO332061B1 (de) |
| NZ (3) | NZ544079A (de) |
| PL (2) | PL211884B1 (de) |
| PT (2) | PT1478659E (de) |
| RU (2) | RU2425053C2 (de) |
| SA (1) | SA04240478B1 (de) |
| SG (2) | SG185137A1 (de) |
| UA (1) | UA83989C2 (de) |
| WO (1) | WO2003006492A2 (de) |
| ZA (2) | ZA200401108B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210294C (zh) | 2001-07-13 | 2005-07-13 | 一泰医药研究（深圳）有限公司 | 序列号21的生物活性肽 |
| WO2004055042A1 (en) * | 2002-12-18 | 2004-07-01 | Pepharm R & D Limited | Biologically active peptide conjugates |
| TWI322815B (en) * | 2003-06-26 | 2010-04-01 | Cms Peptides Patent Holding Company Ltd | Biologically active peptide comprising tyrosyl-seryl-valine (ysv) |
| TWI353252B (en) * | 2004-04-28 | 2011-12-01 | Cms Peptides Patent Holding Company Ltd | Biologically active peptide vapeehptllteaplnpk der |
| CN1799623B (zh) * | 2005-01-05 | 2011-01-26 | 康哲医药研究(深圳)有限公司 | 生物活性肽在制备用于防治关节炎的药物中的用途 |
| CN101501062B (zh) * | 2005-07-26 | 2012-07-18 | 康哲医药研究(深圳)有限公司 | 新型生物活性肽及其新用途 |
| GB0918579D0 (en) * | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| RU2615908C1 (ru) * | 2016-05-16 | 2017-04-11 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242821A (en) | 1989-07-10 | 1993-09-07 | Valio, Finnish Co-Operative Dairies' Association | Lactococcus promoter and signal sequences for expression in bacteria |
| IT1231156B (it) | 1989-07-19 | 1991-11-19 | Eniricerche Spa | Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento. |
| WO1991009613A1 (en) * | 1989-12-22 | 1991-07-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Synthetic peptides as modulators of functional responses of intact cells |
| US5556744A (en) * | 1992-05-29 | 1996-09-17 | The Trustees Of The University Of Pennsylvania | Methods and compositions for diagnosing and treating certain HIV infected patients |
| DE69433299T2 (de) | 1993-06-15 | 2004-09-09 | E.I. Du Pont De Nemours And Co., Wilmington | Rekombinante spinnerseide analoge |
| JP3286420B2 (ja) | 1993-09-28 | 2002-05-27 | 株式会社ユニシアジェックス | 内燃機関の吸排気弁駆動制御装置 |
| JPH10503643A (ja) | 1994-06-17 | 1998-04-07 | ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー | 微生物中に遺伝物質を導入する方法およびその方法によってえられる形質転換体 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5958416A (en) * | 1994-12-16 | 1999-09-28 | Regents Of The University Of Minnesota | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| ATE273322T1 (de) | 1995-10-24 | 2004-08-15 | Chemo Sero Therapeut Res Inst | Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren |
| GB9606016D0 (en) * | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
| US5861483A (en) | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| SE9603468D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
| GB9710762D0 (en) * | 1997-05-23 | 1997-07-23 | Cancer Res Inst Royal | Binding complexes |
| JP3366339B2 (ja) | 1997-05-27 | 2003-01-14 | ハニル シンセティック ファイバー カンパニー リミテッド | 高効率発現ベクターを用いてサッカロミセスセレビジエから再組合蛋白質を製造する方法 |
| KR19990024297A (ko) | 1997-08-07 | 1999-04-06 | 오종석 | 인체 구강내 치태형성을 억제하는 신규한 유산균 |
| US6100388A (en) | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
| US6653076B1 (en) * | 1998-08-31 | 2003-11-25 | The Regents Of The University Of Washington | Stable isotope metabolic labeling for analysis of biopolymers |
| US6413530B1 (en) * | 1999-04-21 | 2002-07-02 | University Of Florida Research Foundation, Inc. | Pesticidal peptides |
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| AU1197001A (en) * | 1999-10-29 | 2001-05-14 | Institute For Applied Biomedicine | B cell clonal toxins and methods for using the same |
-
2002
- 2002-07-11 JP JP2003512262A patent/JP4213581B2/ja not_active Expired - Fee Related
- 2002-07-11 AU AU2002319423A patent/AU2002319423B2/en not_active Ceased
- 2002-07-11 KR KR1020047000499A patent/KR100889993B1/ko not_active IP Right Cessation
- 2002-07-11 CA CA2452417A patent/CA2452417C/en not_active Expired - Lifetime
- 2002-07-11 PL PL383101A patent/PL211884B1/pl unknown
- 2002-07-11 DK DK07000950.1T patent/DK1790655T3/da active
- 2002-07-11 DE DE60229883T patent/DE60229883D1/de not_active Expired - Lifetime
- 2002-07-11 UA UA2004021049A patent/UA83989C2/ru unknown
- 2002-07-11 AT AT02749008T patent/ATE414099T1/de not_active IP Right Cessation
- 2002-07-11 NZ NZ544079A patent/NZ544079A/en not_active IP Right Cessation
- 2002-07-11 PT PT02749008T patent/PT1478659E/pt unknown
- 2002-07-11 RU RU2007108896/10A patent/RU2425053C2/ru not_active IP Right Cessation
- 2002-07-11 ES ES07000950T patent/ES2345842T3/es not_active Expired - Lifetime
- 2002-07-11 RU RU2004104335/13A patent/RU2305107C2/ru active
- 2002-07-11 DE DE60236330T patent/DE60236330D1/de not_active Expired - Lifetime
- 2002-07-11 EP EP02749008A patent/EP1478659B1/de not_active Expired - Lifetime
- 2002-07-11 EP EP08005150A patent/EP1947109A3/de not_active Withdrawn
- 2002-07-11 DK DK02749008T patent/DK1478659T3/da active
- 2002-07-11 EP EP07000950A patent/EP1790655B1/de not_active Expired - Lifetime
- 2002-07-11 AT AT07000950T patent/ATE466871T1/de not_active IP Right Cessation
- 2002-07-11 WO PCT/GB2002/003203 patent/WO2003006492A2/en active Application Filing
- 2002-07-11 SG SG2010039980A patent/SG185137A1/en unknown
- 2002-07-11 MY MYPI20022635A patent/MY138219A/en unknown
- 2002-07-11 MX MXPA03011190A patent/MXPA03011190A/es active IP Right Grant
- 2002-07-11 ES ES02749008T patent/ES2316586T3/es not_active Expired - Lifetime
- 2002-07-11 BR BR0210252-8A patent/BR0210252A/pt active Search and Examination
- 2002-07-11 PL PL368059A patent/PL208666B1/pl unknown
- 2002-07-11 SG SG200508362-1A patent/SG142165A1/en unknown
- 2002-07-11 NZ NZ553507A patent/NZ553507A/en not_active IP Right Cessation
- 2002-07-11 IL IL15982702A patent/IL159827A0/xx active IP Right Grant
- 2002-07-11 KR KR1020077013319A patent/KR100889992B1/ko not_active IP Right Cessation
- 2002-07-11 PT PT07000950T patent/PT1790655E/pt unknown
- 2002-07-11 NZ NZ529879A patent/NZ529879A/en not_active IP Right Cessation
- 2002-07-11 CA CA2707767A patent/CA2707767C/en not_active Expired - Fee Related
-
2004
- 2004-01-12 NO NO20040134A patent/NO332061B1/no not_active IP Right Cessation
- 2004-01-17 SA SA04240478A patent/SA04240478B1/ar unknown
- 2004-02-11 ZA ZA200401108A patent/ZA200401108B/en unknown
- 2004-12-02 HK HK04109575.0A patent/HK1066552A1/xx not_active IP Right Cessation
-
2005
- 2005-12-05 ZA ZA200509838A patent/ZA200509838B/xx unknown
-
2007
- 2007-06-08 HK HK07106170.2A patent/HK1098767A1/xx not_active IP Right Cessation
- 2007-06-26 IL IL184227A patent/IL184227A/en not_active IP Right Cessation
- 2007-07-19 JP JP2007187713A patent/JP2007312785A/ja active Pending
- 2007-07-25 NO NO20073914A patent/NO20073914L/no not_active Application Discontinuation
-
2008
- 2008-05-29 JP JP2008140488A patent/JP4316651B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366742C (zh) | Il-2选择性激动剂和拮抗剂 | |
| EP1315513B1 (de) | "pseudo"-native chemische ligation | |
| RU2292352C9 (ru) | Ингибитор и стимулятор пролиферации стволовой клетки и их использование | |
| CN103450348B (zh) | 一种促红细胞生成素模拟肽、其制备方法和用途 | |
| TW458984B (en) | Novel mutant hIL-4 proteins as antagonists or partial agonists of human interleukin 4 | |
| EA021867B1 (ru) | Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций | |
| HU218007B (hu) | Eljárás random bio-oligomer könyvtár előállítására valamint, alkalmazására | |
| EP0335423A2 (de) | Modifizierter humaner G-CSF | |
| US10875903B2 (en) | Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof | |
| CN101432428A (zh) | 重组人干扰素样蛋白 | |
| EA003940B1 (ru) | Усеченный по амино-концу хемокин rantes и способы его использования | |
| JPS62174026A (ja) | 白血球減少症治療剤 | |
| CN110248953A (zh) | 新型订书肽及其用途 | |
| ZA200401108B (en) | Biologically active peptides | |
| CN111620932A (zh) | 一种多肽及在促进nk细胞增殖和提高其对肿瘤细胞杀伤力方面的应用 | |
| CN111718399A (zh) | 一种多肽及用于nk细胞培养、制备nk细胞培养基的用途 | |
| CA2301499A1 (en) | T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof | |
| US6906170B1 (en) | Anti-inflammatory peptides derived from IL-2 and analogues thereof | |
| CN102131518B (zh) | 包含白介素-11类似物的生物聚合物缀合物 | |
| CN102775502A (zh) | α干扰素融合蛋白 | |
| EP0138616A2 (de) | Nona- und Dekapeptiden mit vergrösserter zellentötender Wirksamkeit, Verfahren für deren Herstellung und deren pharmazeutische Zusammensetzungen | |
| CN106928335A (zh) | 用于肿瘤的Her-2多肽、组合物及制备方法和应用 | |
| CN111499723B (zh) | 一种嵌合抗原受体及其应用 | |
| CN101142234A (zh) | 结合红细胞生成素受体的新肽 | |
| CN102168057B (zh) | 表达多活性肽的工程菌及制备混合多肽的方法 |